Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020

THOUSAND OAKS, Calif., Dec. 5, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the first presentation of clinical safety and efficacy data from the Phase 1 study of AMG 701 in heavily pre-treated patients with relapsed/refractory multiple myeloma (R/R MM). AMG 701 is an...

from PR Newswire: https://ift.tt/2Jvmhqs